AstraZeneca Results Presentation Deck

Emerging markets Diverse and solid growth $m 2,500 2,000 1,500 - 1,000 500 - Q1 2018 Q2 2018 Q3 2018 Q4 2018 Emerging markets +10% EMs ex China +9%; China +11% Q1 2019 Q2 2019 Q3 2019 Q4 2019 Q1 2020 Q2 2020 Q3 2020 Q4 2020 China EMs ex China Total revenue at actual exchange rates; changes at CER and for FY 2020, unless stated otherwise. 18 Performance driven by new medicines +59% (33% of total revenue; $1.1bn¹ incrementally) Oncology +36%: Tagrisso ($1.2bn); March 2021 NRDL inclusion New CVRM +31%: Forxiga (+55%) ; Brilinta (+4%) Respiratory & Immunology -18%: Pulmicort COVID-19 hit ($798m, -33%), but Symbicort continued up ($567m, +9%) Diversified growth: AP2 +6%, MEA³ +1%, LA4 +13%, Russia +42% Major 2020 NRDL inclusions: Lynparza, Forxiga, roxadustat Major 2020 VBP inclusions: Brilinta, legacy Gl medicines5 Revenue anticipated to continue growing ahead of the long-term ambition of mid to high single-digit growth Total revenue at actual exchange rates; changes at CER and for FY 2020, unless stated otherwise. 1. Total revenue at CER 2. Asia Pacific 3. Middle East, Africa and other 4. Latin America 5. Gastrointestinal; Losec, Nexium. 4

View entire presentation